Rocket Pharma gets FDA nod for first pediatric gene therapy targeting severe LAD-I
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Subscribe To Our Newsletter & Stay Updated